Welcome to our dedicated page for Karuna Therapeutics news (Ticker: KRTX), a resource for investors and traders seeking the latest updates and insights on Karuna Therapeutics stock.
Karuna Therapeutics, Inc. (NASDAQ: KRTX) is a clinical-stage biopharmaceutical leader developing innovative treatments for neuropsychiatric disorders. This page provides comprehensive access to official company announcements and verified news updates regarding their pioneering therapies.
Investors and medical professionals will find timely updates on KarXT clinical trials, regulatory developments, and strategic partnerships. Our curated news feed covers essential milestones including trial results analysis, FDA communications, and research collaborations in the CNS therapeutic space.
Key focus areas include progress reports on schizophrenia and Alzheimer's disease treatment candidates, financial updates supporting pipeline development, and expert commentary on muscarinic receptor modulation science. All content is sourced directly from company filings and reputable industry publications.
Bookmark this page for streamlined access to critical updates about one of biopharma's most promising neuropsychiatric treatment developers. Check regularly for new developments in Karuna's mission to address unmet needs in mental health therapeutics.
Karuna Therapeutics (NASDAQ: KRTX) will hold a conference call and webcast on May 4, 2023, at 8:00 a.m. ET to discuss its first quarter 2023 financial results and provide a general business update.
The live webcast will be available on the Investor Relations page of Karuna’s website, and a replay will be accessible for up to 30 days after the event. Karuna Therapeutics focuses on developing innovative treatments for psychiatric and neurological disorders, aiming to address the unmet needs of patients facing these challenges.
Karuna Therapeutics, Inc. (NASDAQ: KRTX) has successfully closed its underwritten public offering of 2,851,299 shares of common stock, including 371,908 shares purchased by underwriters at a public offering price of $161.33 each. The offering generated approximately $460 million in gross proceeds for the company, prior to underwriting discounts and estimated expenses. The shares were offered under an effective shelf registration statement previously filed with the SEC. Goldman Sachs, J.P. Morgan, and Morgan Stanley led the offering as joint book-running managers.
Karuna Therapeutics, Inc. (NASDAQ: KRTX) announced its participation in the Stifel 2023 CNS Days on March 29, 2023, at 8:00 a.m. ET. During the event, management will present updates on their innovative biopharmaceutical efforts aimed at developing transformative treatments for psychiatric and neurological conditions. A live webcast of the presentation will be accessible on the company's Investor Relations page, with a replay available for 30 days post-event. Karuna is committed to advancing effective therapies to improve patient outcomes in severe mental health disorders.
Karuna Therapeutics (NASDAQ: KRTX) has announced a public offering of 2,479,391 shares of common stock, priced at
Karuna Therapeutics has announced a public offering of $400 million of common stock, with an additional $60 million option for underwriters. The offering will be managed by Goldman Sachs, J.P. Morgan, and Morgan Stanley. Proceeds will support the company’s initiatives in psychiatric and neurological conditions. The offering is subject to market conditions, and specifics will be detailed in a prospectus supplement filed with the SEC. This initiative highlights Karuna's commitment to expanding its capabilities, though actual outcomes hinge on market acceptance and completion of the offering.
FAQ
What is the market cap of Karuna Therapeutics (KRTX)?
